What is the clinical evidence from this study?

Study design: Observational. Population: Complex congenital heart disease (n=40). Intervention: Complex congenital heart disease vs. Structurally normal hearts. Primary outcome: S-ICD eligibility (p=> 0.05).

What does this research mean for the field?

Patients with complex congenital heart disease demonstrate subcutaneous implantable cardioverter-defibrillator (S-ICD) eligibility comparable to individuals with structurally normal hearts. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

February 11, 2015EP EuropaceOpen Access

Potential eligibility of congenital heart disease patients for subcutaneous implantable cardioverter-defibrillator based on surface electrocardiogram mapping

View Full Paper

Ask AI

Bookmark

Key result

Complex congenital heart disease patients show similar S-ICD eligibility to controls with structurally normal hearts.

P>0.05
n=40

Why the study?

The eligibility of complex congenital heart disease patients for subcutaneous implantable cardioverter-defibrillator has yet to be determined.

Does complex congenital heart disease affect S-ICD eligibility based on surface ECG mapping compared to structurally normal hearts?

Population

30 patients with complex congenital heart disease and 10 controls with structurally normal hearts

Comparison

Complex congenital heart disease patients vs controls with structurally normal hearts

Design

Observational study using Boston Scientific ECG screening tool

Authors

MZMehmood ZebAyub Medical College GVGruschen VeldtmanAdult Congenital Heart Disease AYArthur YueUniversity Hospital Southampton NHS Foundation Trust

Discussion

Member takes

Implication

S-ICD eligibility appears similar in complex congenital heart disease; extends screening data but leaves open prospective validation.

Study Design

Type

Observational (n=40)

Structured PICO

Does complex congenital heart disease affect S-ICD eligibility based on surface ECG mapping compared to structurally normal hearts?

Population

40 subjects, including 30 patients with complex congenital heart disease and 10 controls with structurally normal hearts, with a mean age of 36.3 years.

Exposure

ECG screening for subcutaneous implantable cardioverter-defibrillator (S-ICD) eligibility using the Boston Scientific ECG screening tool in two and six different postures.

Comparator

Adults with structurally normal hearts.

Outcome

S-ICD eligibility.surrogate

Main Result

Absolute Event Rate: 86.7% vs 100%

p-value: p=> 0.05

Patients with complex congenital heart disease have similar S-ICD eligibility based on ECG screening compared to patients with structurally normal hearts.

Cite This Study

Zeb et al. (2015) conducted an observational in Complex congenital heart disease (n=40). Complex congenital heart disease vs. Structurally normal hearts was evaluated on S-ICD eligibility (p=> 0.05). Complex congenital heart disease patients demonstrated similar S-ICD eligibility compared to controls with structurally normal hearts (86.7% vs 100%, P > 0.05).

synapsesocial.com/papers/6aaddfe9629e0ae2c54f63f0 https://doi.org/10.1093/europace/euu375

Topics

Cardiac device therapy Congenital heart disease adults

View Full Paper

Ask AI

Bookmark

Potential eligibility of congenital heart disease patients for subcutaneous implantable cardioverter-defibrillator based on surface electrocardiogram mapping

Discussion

Member takes

Implication

Study Design

Structured PICO

Main Result

Cite This Study

Topics

Potential eligibility of congenital heart disease patients for subcutaneous implantable cardioverter-defibrillator based on surface electrocardiogram mapping

Discussion

Member takes

Implication

Study Design

Structured PICO

Main Result

Cite This Study

Also Consider

Topics

Also Consider